



12-19-07

ju

16478
C.C.

PATENT

Attorney Docket No: 7640-X05-046

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Dina BEN-YEHUDA et al.
Serial No.: 10/559,639
Filed: July 24, 2006
Art Unit: 1647
Confirmation No.: 5095
Title: LIVIN-DERIVED PEPTIDES, COMPOSITIONS AND USES THEREOF

CERTIFICATE OF EXPRESS MAILING


PATENTS

EXPRESS "Express Mail" Mailing Label number EV 820314495 US
Date of December 18, 2007

I hereby certify that the attached paper(s) or fee(s) is/are being deposited with the United States Postal Services "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date indicated above and is addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Estefania Belaunde
(Signature of person mailing paper or fee)

ESTEFANIA BELAUNDE
(Typed or printed name of person mailing paper or fee)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Dina BEN-YEHUDA et al.

Attorney Docket No.: 7640-X05-046

Serial No.: 10/559,639

Group Art Unit: 1647

Filed: July 24, 2006

Confirmation No.: 5095

For: LIVIN-DERIVED PEPTIDES, COMPOSITIONS AND USES THEREOF

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Alexandria, VA 22313

Sir:

In accordance with the duty of disclosure provisions of 37 CFR § 1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject US patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

I. 37 CFR § 1.97 Basis. This Information Disclosure Statement is filed:

A. under 37 CFR § 1.97(b);

1. within three months of filing national application or the date of entry of an international application; or
2. before mailing date for first office action on the merits; or
3. before the mailing of a first office action after the filing of a request for continued examination under § 1.114.

B. under 37 CFR § 1.97(c) after the 37 CFR § 1.97(b) time period, but before the mail date of any final office action, notice of allowance, or any action that otherwise closes prosecution in the application, together with either:

1. a certification statement under 37 CFR § 1.97(e) (see II(A) below), or
2. a \$180.00 fee under 37 CFR § 1.17(p).

C. under 37 CFR 1.97(d) after the 37 CFR § 1.97(c) time period, but before payment of the issue fee, together with:

1. a certification statement under 37 CFR § 1.97(e) (see II(B) below), and
2. a \$180.00 fee under 37 CFR § 1.17(p).

12/19/2007 SSANDAR1 0000003 10559639

01 FC:1806

180.00 DP

II. Certification. Certification statement applicable if item I(B)(1) or I(C)(1) is checked:

A. In accordance with 37 CFR § 1.97(e)(1), it is certified that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

B. In accordance with 37 CFR § 1.97(e)(2), it is certified that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known by any individual designated in 37 CFR § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

III. Attachments. United States patent documents are not being submitted pursuant to 37 CFR § 1.98(a). Enclosures accompany this Information Disclosure Statement are:

A. foreign search reports
B. foreign patent documents
C. other publications listed on the attached PTO-1449, PTO/SB08a or PTO/SB08b

IV. Documents previously submitted for continuing applications.

A. This application is a continuing application; accordingly, copies of publications listed on the attached Form PTO-1449, PTO/SB08a or PTO/SB08b from prior application no. _____, filed on _____, of which this publication claims priority under 35 USC § 120, are not being submitted pursuant to 37 CFR § 1.98(d).

V. Supplemental Information Disclosure Statement (check either V(A) or V(B))

A. This Supplemental Information Disclosure Statement filed under 37 CFR § 1.97(f) supplements the Information Disclosure Statement filed on _____. A bona fide attempt was made to comply with 37 CFR § 1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this


Supplemental Information Disclosure Statement can be considered as if properly filed on _____.

B. This Supplemental Information Disclosure Statement is timely filed within one (1) month of a USPTO notice under 37 CFR § 1.97(i).

VI. No admission. No admission is made that the information cited in this Information Disclosure Statement is, or is considered to be, material to patentability. No representation is made by the filing of this Information Disclosure Statement that a search has been made 37 CFR §§ 1.97.

VII. Payment. If a fee is due pursuant to the above, payment by credit card is submitted herewith. The Commissioner is authorized to charge any additional or omitted fee required or credit any overpayment for this Information Disclosure Statement and/or Petition to Deposit Account 500601.

Respectfully submitted,


P.D. BIANCO, PH.D.

Paul D. Bianco, Ph.D.
Reg. No. 43,500

FLEIT KAIN GIBBONS GUTMAN BONGINI & BIANCO, PL
21355 EAST DIXIE HIGHWAY
SUITE 115
MIAMI, FL 33180
305/830-2600
305/830-2605 (FAX)